Use of TFPI to Treat Severe Bacterial Infections
AssigneeNovartis AG
InventorsStephen F. Hardy, Yumin Dai
Life of this patent
Estimating the term…
Abstract
Methods for prophylactically or therapeutically treating a patient at risk of developing or diagnosed as having a severe bacterial infection involving administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog at low doses to avoid adverse side effects.
Claims20
A method of (1) treating a patient at risk of developing or diagnosed as having a severe bacterial infection or (2) reducing the risk of mortality from a severe bacterial infection, comprising administering TFPI or a TFPI analog to a patient in need thereof who meets one or more of the following criteria:
- (a) a blood DL-6 level below 3,200 pg/ml;
- (b) an International Normalized Ratio (ESfR) below 2.5;
- (c) an acute physiology score (APS) less than 26;
- (d) an Acute Physiology And Chronic Health Evaluation (APACHE II) score less than 38;
- and
- (e) a MODS score greater than 18.
(canceled)
9-14. (canceled)
(canceled)
18-27. (canceled)
29-31. (canceled)
33-36. (canceled)
Dependencies are inferred from the claim text.